Ably Medical is a Norwegian health technology innovation company with expertise in industrial design, sensor technology, computer science, human factors and organisational psychology. Ably Medical presents the next generation hospital bed that reduces falls, pressure ulcers and nurse load by state-of-the-art innovative use of sensor technology, mechanical design, and machine learning capacity.
The Ably Bed learns, knows, mobilises the patient and collaborates with the medical staff to provide a robust and innovative health care service. Ably Bed is inspired by the professional spirit found among the nursing and medical personnel themselves. The ability of the bed to assist patient movements is modelled from the human spine.
The Ably Medical and MaRS EXCITE study is set to validate the Ably Bed value in hospital settings. The study will document the superiority to standard hospital beds in the market by significantly reduce pressure ulcers, fall and nurse load.
Aegis Medical Innovations
Aegis Medical Innovations Inc. was founded with a mission to commercialize a minimally invasive cardiovascular technology to help prevent strokes in patients with atrial fibrillation (AF). Aegis is working in close partnership with Mayo Clinic to develop a simpler, cheaper and safer percutaneous epicardial procedure for left atrial appendage (LAA) closure called the Sierra Ligations System (Sierra). Following a successful first in human study conducted in 2012, the LASSO-AF clinical study is underway in North America to show the safety and procedural success of the Sierra procedure.
Aegis is confident the results will show that Sierra provides significant advantages over all existing treatments for the patient, physician and payers.
Mild brain injury is very common and accounts for 66-75% of all hospital admissions for head trauma. Most persons with mild TBI generally report a similar pattern of symptoms which include physical, cognitive and emotional/behavioral challenges. Common symptoms following the injury include poor concentration, memory problems, irritability, headaches, fatigue, depression, anxiety, dizziness and increased sensitivity to sound and light (Alves, 1992; Miller, 1993; Slagle 1990). This cluster of symptoms has been estimated to affect 50-80% of individuals within three months after a mild TBI (Mittenberg & Burton, 1994; Long & Novack, 1986). Post-concussive syndrome (PCS) can last from months to years following injury the initial injury (Gouvier et al., 1992). These symptoms are very distressing and often result in difficulties in activities of daily living and/or an inability to return to prior employment. Some people will continue to experience symptoms long after their injury, even if brain scans (i.e., MRIs, CT, EEG) are completely normal. Most studies suggest that approximately 15% of these individuals will continue to report symptoms one year post injury (Satz et al., 1999).
APEXK propose that visual-cognitive dysfunctions and related symptoms caused by mild/blast traumatic brain injury (m/bTBI) induces could be resolved by a specific rehabilitation procedure utilizing APEXK’s device and protocols
The first element of our technology is a software (SIMIAN) that collects different independent visual-cognitive functional parameters through a clinical interface. These parameters are then processed through an intelligent algorithm that generates an integrative visual-cognitive profile called CVCP (characterized visual-cognitive profile), which is used to track patient progression throughout the rehabilitation process. In addition, our software records patient symptomatology. The second element of our technology is a device (CEBUS) that is used both in evaluation and rehabilitation. This platform provides visual and audio stimulations across a person’s visual field, enabling evaluation and oculomotor re-training. The other function of the device is to evaluate/re-train a cognitive reactional field through a complex cognitive reactional task. Through this protocol, it is possible to generate a cognitive reactional mapping representing speed of processing in relation to visual field stimulation, and to generate controlled cognitive overload, allowing concussed patients to be re-introduced to increasing levels of cognitive stimulation.
The EXCITE study will help determine the efficacy and value of APEXK device and protocol for patient with persistent symptoms of concussion.
Assurex Canada helps healthcare providers tailor the right treatment to patients using a genetic test called GeneSight™ , which is displacing the current trial and error approach to prescribing medication for behavioral health conditions.
GeneSight™ technology is based on combinatorial pharmacogenomics (CPGx™), a proprietary informatics platform that integrates and weights the importance of multiple genes that affect an individual’s ability to tolerate and respond to 33 Health Canada approved medications commonly prescribed to treat depression and schizophrenia, as well as anxiety, posttraumatic stress disorder (PTSD), bipolar disorder and other behavioral health conditions.
Within 36 hours of receiving a DNA sample collected with a simple cheek swab, Assurex Canada’s laboratory will send a report to the patient’s healthcare provider that groups medications into the categories of “use as directed,” “use with caution” and “use with increased caution and with more frequent monitoring” based upon a patient’s genetic profile and the genetic pathways through which medications work in the body.
GeneSight™ was developed in the Assurex Health clinical laboratory and is based on patented technology licensed from Mayo Clinic and Cincinnati Children’s Hospital Medical Center. It also incorporates genetic markers discovered by the Centre for Addiction and Mental Health (CAMH). GeneSight™ helps healthcare providers more quickly find an effective treatment for their patients and may save patients from experiencing side effects that often come from taking antidepressants and antipsychotics.
Cochlear Canada Inc.
Cochlear Canada is an incorporation of Cochlear Limited, a global medical device leader in designing and manufacturing surgically implantable hearing devices, including cochlear implants, bone conduction implants, and hybrid electro-acoustic implants; each addressing a different type of hearing loss. The company’s hearing implants have helped more than 500,000 people around the world hear.
Cochlear Ltd was formed in 1981 in Australia and its products are supplied to over 100 countries internationally. Cochlear has been named one of the world’s most innovative companies by Forbes. To continue its innovative status, Cochlear invests more than US$115 million each year in R&D and currently participates in more than 100 collaborative research programs worldwide.
Cochlear is missioned to help people hear and be heard, to empower people to connect with others and live a full life, to transform the way people understand and treat hearing loss, and to innovate and bring to market a range of implantable hearing solutions that deliver a lifetime of hearing outcomes. Not many companies have the privilege to be able to change people’s lives by giving them back one of their lost senses; Cochlear is one of those companies.
Roche Diagnostics has built its success on innovation. As the world leader in in vitro diagnostics, Roche supplies a wide range of rapid, reliable instruments and tests for disease screening and diagnosis in laboratories, at the point of care, and for patient self-management.
Roche Diagnostics Point of Care delivers a comprehensive range of rapid, cost-effective and user-friendly diagnostic systems designed to measure a variety of clinically relevant parameters. The CoaguChek® system is the leading professional and patient PT/INR point-of-care testing meter in Canada providing accurate PT/INR values from a single drop of blood within one minute, enabling immediate results and adjustment of medication with minimal discomfort to the patient. Roche Diagnostics Canada offers two models of INR test meters using the same test strips, with dedicated features to fulfill patient and professional needs: the Coaguchek® XS system for patients and the Coaguchek® XS Pro for Healthcare Professionals.
The CoaguChek® system shows highly comparable results with the gold standard reference method of the World Health Organization (WHO) and an excellent correlation to laboratory analyzers. The use of point-of-care testing (POCT) coagulation monitoring devices is recommended by Canadian health technology assessment agencies (HTAs) for professional use and for patient INR self-monitoring, when appropriate.
Roche Diagnostics, with the support of MaRS EXCITE will set out to show that a broader adoption in the healthcare system of POC INR monitoring will provide equitable access for all eligible patients to high quality anticoagulation management while addressing the burden of increased costs associated with anticoagulation therapy.
Alzheimer’s disease (AD) is the most prevalent disorder underlying dementia as well as one of the foremost causes of morbidity and mortality in the aging population. It affects not only those afflicted by the disorder but also places a heavy burden upon their families.
Though a few approved pharmacotherapies do exist for the treatment of AD, these produce symptomatic improvements but are not curative nor have been demonstrated to slow the progression of the disease. Thus, family members of AD patients are faced with the eventual decision of becoming at-home caregivers or relying on long-term care facilities. Home care assistance can help to lengthen the time AD patients are able to remain living in the community, yet a significant number of patients eventually require long-term care facilities. Severe declines in cognition also result in increased accidents and emergency department visits, often resulting in long-term hospitalization.
The Vielight Neuro RX Gamma device is a portable, wearable, low-light level therapy delivery device that administers near-infrared light to the brain trans-cranially and intranasally. The device can be applied by the patient or caregiver at home and does not require specialized training